Cost effectiveness of prostacyclins in pulmonary arterial hypertension

被引：0
|
作者：
Antonio Roman
Joan A. Barberà
Pilar Escribano
Maria L. Sala
Laia Febrer
Itziar Oyagüez
Eliazar Sabater
Miguel Á. Casado
机构：
[1] CIBERES,Department of Pneumology, Hospital Universitari Vall d’Hebron
[2] Hospital Clínic i Provincial de Barcelona,Department of Pneumology
[3] Hospital Universitario,Department of Cardiology
[4] Hospital de la Santa Creu i Sant Pau,Department of Pharmacy
[5] Bayer HealthCare,Market Access Department
[6] Pharmacoeconomics & Outcomes Research Iberia,undefined
[7] Hospital Universitari Vall d’Hebron,undefined
来源：
Applied Health Economics and Health Policy | 2012年 / 10卷 / 3期
关键词：
Pulmonary Arterial Hypertension; Prostacyclin; Bosentan; Iloprost; Epoprostenol;
D O I：
10.2165/11630780-000000000-00000
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：175 / 188
页数：13
相关论文
共 50 条
  • [1] Cost Effectiveness of Prostacyclins in Pulmonary Arterial Hypertension
    Roman, Antonio
    Barbera, Joan A.
    Escribano, Pilar
    Sala, Maria L.
    Febrer, Laia
    Oyagueez, Itziar
    Sabater, Eliazar
    Casado, Miguel A.
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2012, 10 (03) : 175 - 188
  • [2] Prostacyclins and pulmonary arterial hypertension in children
    Wu, Y.
    Liu, H-M
    Gu, L.
    Li, Q-W
    Zhu, L.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (01) : 37 - 45
  • [3] Pulmonary Arterial Hypertension: A Focus on Infused Prostacyclins
    Stewart, Traci
    [J]. JOURNAL OF INFUSION NURSING, 2016, 39 (05) : 315 - 326
  • [4] Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy
    Jean-Luc Vachiéry
    [J]. Advances in Therapy, 2011, 28 : 251 - 269
  • [5] Prostacyclins in Pulmonary Arterial Hypertension: the Need for Earlier Therapy
    Vachiery, Jean-Luc
    [J]. ADVANCES IN THERAPY, 2011, 28 (04) : 251 - 269
  • [6] Safe and effective use of prostacyclins to treat pulmonary arterial hypertension
    Coons, James C.
    Clarke, Megan
    Wanek, Matthew R.
    Bauer, Abby
    Bream-Rouwenhorst, Heather R.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (19) : 1716 - 1723
  • [7] Risk assessment in pulmonary arterial hypertension treated with prostacyclins: a retrospective analysis
    Dendievel, Renaud
    Vachiery, Jean-Luc
    Dewachter, Celine
    [J]. ACTA CARDIOLOGICA, 2020, 75 : 20 - 21
  • [8] Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension
    Parikh, Kishan S.
    Doerfler, Sean
    Shelburne, Nicholas
    Kennedy, Karla
    Whitson, Jordan
    Dahhan, Talal
    Fortin, Terry
    Rajagopal, Sudarshan
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 75 (04) : 299 - 304
  • [9] Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
    You, Ruxu
    Qian, Xinyu
    Tang, Weijing
    Xie, Tian
    Zeng, Fang
    Chen, Jun
    Zhang, Yu
    Liu, Jinyu
    [J]. CANADIAN RESPIRATORY JOURNAL, 2018, 2018
  • [10] COST EFFECTIVENESS OF DRUGS FOR PULMONARY ARTERIAL HYPERTENSION: A CANADIAN STUDY
    Coyle, K.
    Coyle, D.
    Jabr, M.
    Blouin, J.
    Lee, K.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A143 - A143
12345